Format
Sort by

Send to:

Choose Destination

Search results

Items: 4

1.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.

von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP.

J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14. doi: 10.1007/s00432-014-1678-3. Epub 2014 May 10.

2.

Thrombin-induced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase.

Vallon M, Aubele P, Janssen KP, Essler M.

Biochem J. 2012 Feb 1;441(3):937-44. doi: 10.1042/BJ20111682.

PMID:
22013897
3.

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V.

BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367.

4.

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.

Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, Stemmler HJ, Kirchner T, Heinemann V.

Anticancer Drugs. 2011 Oct;22(9):913-8. doi: 10.1097/CAD.0b013e3283493160.

PMID:
21795973
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk